Safety of intravitreal injection of ranibizumab in early pregnancy: a series of three cases
Safety of intravitreal injection of ranibizumab in early pregnancy: a series of three cases, Published online: 19 January 2018; doi:10.1038/eye.2017.305Safety of intravitreal injection of ranibizumab in early pregnancy: a series of three cases (Source: Eye)
Source: Eye - January 19, 2018 Category: Opthalmology Authors: P Fossum C Couret B Briend M Weber L Lagarce Source Type: research

Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes
To evaluate the efficacy and safety of ranibizumab 0.5 mg in adult patients with macular edema (ME) resulting from any cause other than diabetes, retinal vein occlusion, or neovascular age-related macular degeneration. (Source: Ophthalmology)
Source: Ophthalmology - January 19, 2018 Category: Opthalmology Authors: Giovanni Staurenghi, Timothy Y.Y. Lai, Paul Mitchell, Sebastian Wolf, Andreas Wenzel, Jun Li, Amitabha Bhaumik, Philip G. Hykin, PROMETHEUS Study Group Tags: Original Article Source Type: research

PRN Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Ocular Histoplasmosis
Ocular histoplasmosis syndrome (OHS) is a systemic disease thought to be caused by the inhalation and systemic spread of the dimorphic fungal organism Histoplasma capsulatum. A mild systemic infection occurs after the initial infection and results in granulomatous inflammation and resultant encapsulation primarily in the lungs and the choroid. The classic ocular findings for OHS include peripheral chorioretinal scarring ( “histo spots”), peripapillary atrophy and hyperplasia, and maculopathy (or choroidal neovascularization [CNV]). The development of CNV is the primary ocular complication (Source: Ophthalmic Su...
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - January 10, 2018 Category: Opthalmology Authors: Edward H. Wood, MD Source Type: research

Antiplatelet and anticoagulant drugs do not affect visual outcome in neovascular age-related macular degeneration in the BRAMD trial
To determine if use of antiplatelet or anticoagulant (AP/AC) medication influences visual acuity in patients with active neovascular age-related macular degeneration (N-AMD). (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - January 9, 2018 Category: Opthalmology Authors: Gabri ëlle H.S. Buitendijk, Ann-Sofie M.E. Schauwvlieghe, Johannes R. Vingerling, Reinier O. Schlingemann, Caroline C.W. Klaver, comparing Bevacizumab to Ranibizumab in Age-related Macular Degeneration (BRAMD) trial research group Tags: Original Articles Source Type: research

Safety and Efficacy of Ranibizumab for Retinopathy of Prematurity
This randomized clinical trial tests the safety and efficacy of 2 different doses of ranibizumab for retinopathy of prematurity. (Source: JAMA Pediatrics)
Source: JAMA Pediatrics - January 8, 2018 Category: Pediatrics Source Type: research

Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
CONCLUSIONS: Implications for practice: Intravitreal bevacizumab/ranibizumab, when used as monotherapy, reduces the risk of refractive errors during childhood but does not reduce the risk of retinal detachment or recurrence of ROP in infants with type 1 ROP. While the intervention might reduce the risk of recurrence of ROP in infants with zone I ROP, it can potentially result in higher risk of recurrence requiring retreatment in those with zone II ROP. Intravitreal pegaptanib, when used in conjunction with laser therapy, reduces the risk of retinal detachment as well as the recurrence of ROP in infants with type 1 ROP. How...
Source: Cochrane Database of Systematic Reviews - January 8, 2018 Category: General Medicine Authors: Sankar MJ, Sankar J, Chandra P Tags: Cochrane Database Syst Rev Source Type: research

Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases: An Audit.
Conclusion: Anti VEGFs have become an invaluable tool in the management of a number of retinal diseases in our center. However, the cost implications are a hindrance to an increased uptake of this form of treatment. Cheaper alternative preparations should be made available to encourage the uptake. Government in developing countries should be encouraged to bear the health burden of the old aged pensioner (OAP). PMID: 29299078 [PubMed] (Source: Open Ophthalmology Journal)
Source: Open Ophthalmology Journal - January 6, 2018 Category: Opthalmology Tags: Open Ophthalmol J Source Type: research

How vitreomacular interface modifies the efficacy of anti-vegf therapy for myopic choroidal neovascularization
Conclusion: The data show that ranibizumab is effective in controlling mCNV activity when associated with vitreoretinal interface alterations. However, a visual recovery was observed only in patients with uncomplicated mCNV. (Source: RETINA)
Source: RETINA - January 1, 2018 Category: Opthalmology Tags: Original Study Source Type: research

LONG-TIME OUTCOME IN PATIENTS TREATED WITH RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: A 4-Year Study
Purpose: To investigate the long-time visual outcome in patients with diabetic macular edema treated with ranibizumab in an ordinary clinical setting. Methods: One hundred two eyes of 80 patients were followed for 4 years. All patients received a loading dose of 3 monthly ranibizumab 0.5-mg injections. From Month 3 to Month 48, patients received ranibizumab reinjections pro re nata based on disease activity. Results: Excluding deaths, the 4-year visit was completed by 82% of the study eyes. The best-corrected visual acuity improved by 6.6 Early Treatment Diabetic Retinopathy Study letters at 4 years (P (Source: RETINA)
Source: RETINA - January 1, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Use of aflibercept for the management of refractory pseudophakic macular edema in irvine-gass syndrome and literature review
Conclusion: Intravitreal aflibercept may be effective for the treatment of pseudophakic cystoid macular edema. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - January 1, 2018 Category: Opthalmology Tags: Case Report Source Type: research

Adding Dexamethasone to Ranibizumab for Patients With Persistent Diabetic Macular Edema
In this phase 2 randomized clinical trial, the Diabetic Retinopathy Clinical Research Network compares continued ranibizumab treatment alone vs ranibizumab plus dexamethasone in patients with persistent diabetic macular edema. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - January 1, 2018 Category: Opthalmology Source Type: research

Outcome of “treat and monitor” regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion
AbstractPurposeTo compare the efficacy of a modified PRN treatment regimen ( “treat and monitor”) of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.MethodsSeventy eyes of 70 patients with treatment na ïve branch retinal vein occlusion were enrolled. All patients underwent a comprehensive ophthalmic examination, spectral-domain optical coherence tomography, and fluorescein angiography. Patients were randomized 1:1 to receive intravitreal aflibercept (34 eyes) and ranibizumab (36 eyes) with a “t reat and monitor” treatment regimen with monthly...
Source: International Ophthalmology - December 22, 2017 Category: Opthalmology Source Type: research

Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia
Conclusions: Long-term ranibizumab monotherapy treatment induces unchanged or better BCVA compared to baseline after a 9-year treatment in almost all eyes.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - December 21, 2017 Category: Opthalmology Source Type: research

A Simple Vista en Este N úmero
Silva y otros (p. 57) evaluaron la eficacia y seguridad de un r égimen de tratamiento y extensión (T&E) comparado con un r égimen mensual de ranibizumab al 0,5 mg en pacientes con degeneración macular neovascular relacionada con la edad (nAMD). Realizaron un estudio multicentro intervencional aleatorio de 12 meses, Fase IIIb, de 650 pacientes con diagnóstico reciente de nAMD aceptados para estudio de diciembre de 201 3 a noviembre de 2015 en 90 centros de 18 países. Los investigadores encontraron que los pacientes lograban mejorías en la agudeza visual mejor corregida ta...
Source: Ophthalmology - December 18, 2017 Category: Opthalmology Authors: Sandeep Ravindran Tags: This issue at a glance Source Type: research

This Issue at a Glance
Silva et  al (p. 57) evaluated the efficacy and safety of a treat and extend (T&E) regimen versus a monthly regimen of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (nAMD). They conducted a 12-month, Phase IIIb, multicenter randomized interventional study of 650 patients with newly diagnosed nAMD enrolled between December 2013 and November 2015 at 90 centers across 18 countries. The researchers found that patients made similar rapid gains in best-corrected visual acuity under both the T&E and monthly regimens. (Source: Ophthalmology)
Source: Ophthalmology - December 18, 2017 Category: Opthalmology Authors: Sandeep Ravindran Tags: This issue at a glance Source Type: research

Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections.
CONCLUSIONS: The technique of eyelid retraction for intravitreal injection has a low rate of endophthalmitis, similar to the reported rates using a metal lid speculum. This is beneficial for both the physician and the patient as it minimises patient discomfort as well as the duration of the procedure. To our knowledge, this is one of the largest studies performed to date evaluating intravitreal injection-related endophthalmitis. PMID: 29246893 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - December 15, 2017 Category: Opthalmology Authors: Munro M, Williams GR, Ells A, Fielden M, Kherani A, Mitchell P, Ruzicki J, Adatia FA Tags: Br J Ophthalmol Source Type: research

Use of aflibercept for the management of refractory pseudophakic macular edema in irvine-gass syndrome and literature review
Conclusion: Intravitreal aflibercept may be effective for the treatment of pseudophakic cystoid macular edema. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - December 14, 2017 Category: Opthalmology Tags: Case Report Source Type: research

How vitreomacular interface modifies the efficacy of anti-vegf therapy for myopic choroidal neovascularization
Conclusion: The data show that ranibizumab is effective in controlling mCNV activity when associated with vitreoretinal interface alterations. However, a visual recovery was observed only in patients with uncomplicated mCNV. (Source: RETINA)
Source: RETINA - December 14, 2017 Category: Opthalmology Tags: Original Study Source Type: research

LONG-TIME OUTCOME IN PATIENTS TREATED WITH RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: A 4-Year Study
Purpose: To investigate the long-time visual outcome in patients with diabetic macular edema treated with ranibizumab in an ordinary clinical setting. Methods: One hundred two eyes of 80 patients were followed for 4 years. All patients received a loading dose of 3 monthly ranibizumab 0.5-mg injections. From Month 3 to Month 48, patients received ranibizumab reinjections pro re nata based on disease activity. Results: Excluding deaths, the 4-year visit was completed by 82% of the study eyes. The best-corrected visual acuity improved by 6.6 Early Treatment Diabetic Retinopathy Study letters at 4 years (P (Source: RETINA)
Source: RETINA - December 14, 2017 Category: Opthalmology Tags: Original Study Source Type: research

[Real-life Data on the Treatment of Diabetic Macular Oedema in Germany].
Conclusions Results of real life treatment in clinical routine are found to fall behind controlled, prospective trials, as found to the findings in other anti-VEGF indications: mean gain in VA is lower than in prospective trials, and the initial gain cannot be fully maintained over a prolonged time period. Similarly, the number of injections received is markedly lower than in controlled trials. This can partially be explained by differences in study populations and a negative selection bias in longer term results. However, additional barriers that hamper timely treatment tailored to disease activity requirements must be id...
Source: Klinische Monatsblatter fur Augenheilkunde - December 14, 2017 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research

[Time Course of Changes in Visual Acuity After a Single Injection of Aflibercept or Ranibizumab in Neovascular Age-related Macular Degeneration - Analysis of Aggregated Real Life Data].
Conclusion Our data point to the importance of frequent controls accompanied by timely retreatment, as these have a major impact on visual outcome. It therefore appears to be more important to choose a treatment plan that facilitates frequent re-injections than to select either of the two compounds. PMID: 29232758 [PubMed - in process] (Source: Klinische Monatsblatter fur Augenheilkunde)
Source: Klinische Monatsblatter fur Augenheilkunde - December 14, 2017 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research

Diabetic macular oedema treated with intravitreal anti ‐vascular endothelial growth factor – 2–4 years follow‐up of visual acuity and retinal thickness in 566 patients following Danish national guidelines
Abstract PurposeTo investigate long‐term functional and anatomical outcomes, discontinuation patterns, drug switching and rates of nonimprovement in patients treated with ranibizumab pro re nata (PRN) regimen for diabetic macular oedema (DME) according to the Danish national guidelines. MethodsRetrospective cohort study of 566 eyes in 566 patients with centre‐involved DME who started intravitreal treatment with ranibizumab between January 2011 and December 2013 in the Greater Copenhagen region. Data were retrieved from a database and patient records between January 2011 and March 2016 and analysed using mixed‐model s...
Source: Acta Ophthalmologica - December 14, 2017 Category: Opthalmology Authors: Delila Hodzic ‐Hadzibegovic, Birgit Agnes Sander, Tine Juul Monberg, Michael Larsen, Henrik Lund‐Andersen Tags: Original Article Source Type: research

Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results.
Authors: Neves Cardoso P, Pinheiro AF, Meira J, Pedrosa AC, Falcão MS, Pinheiro-Costa J, Falcão-Reis F, Carneiro ÂM Abstract Purpose: To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD. Methods: Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up. Results: 164 eyes were analyzed, 101 eyes switched from bevacizumab (group 1) and 63 from ranibizumab (group 2). One year after the switch, there was an overall nonsignificant mean dec...
Source: Journal of Ophthalmology - December 6, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland
The objective of this study was to investig... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - December 4, 2017 Category: Opthalmology Authors: Oliver Reich, Martin K. Schmid, Roland Rapold, Lucas M. Bachmann and Eva Blozik Tags: Research article Source Type: research

Comparison of the efficacy of intravitreal ranibizumab for choroidal neovascularization due to pathological myopia with and without a dome-shaped macula
Abstract Ranibizumab injection in the treatment of choroidal neovascularization (CNV) secondary to pathologic myopia (PM) with and without a dome-shaped macula (DSM). Prospective observational study. A total of 24 patients (24 eyes) with angiographic evidence of CNV secondary to PM were divided into 2 groups: eyes with a DSM and eyes without DSM. All patients received a baseline intravitreal ranibizumab injection. Additional injections were considered at each follow-up visit. Best-corrected visual acuity (BCVA) and optical coherence tomography were tested monthly through 12 months of follow-up. The mean changes in BCVA...
Source: Medicine - December 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
CONCLUSION: Compounding of ranibizumab and aflibercept for intravitreal use appears to be safe because the endophthalmitis rate does not appear to be different from that of intravitreal bevacizumab. PMID: 29217032 [PubMed - in process] (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - December 1, 2017 Category: Opthalmology Authors: Forooghian F, Albiani DA, Kirker AW, Merkur AB Tags: Can J Ophthalmol Source Type: research

Diabetic macular edema, innovative technologies and economic impact: New opportunities for the Lombardy Region healthcare system?
ConclusionsThis study demonstrates that concentrating all eligible patients within the Ranibizumab regimen is unlikely to represent a cost‐effective strategy. Indeed, significant economic advantages would be achieved by introducing the other licensed alternatives, Dexamethasone implant and Aflibercept, thus optimising DME Italian healthcare expenditure. The results demonstrate DEX as an advantageous technological alternative for the target population affected by DME, both as a first‐ and second‐line treatment option, reducing the economic burden of the pathology for the Regional/National Health Service. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - December 1, 2017 Category: Opthalmology Authors: Emanuela Foglia, Lucrezia Ferrario, Francesco Bandello, Camilla Ferri, Innocente Figini, Michela Franzin, Gianpiera Gambaro, Ugo Introini, Massimo Medaglia, Giovanni Staurenghi, Patrizia Tadini, Andrea Fomiatti, Davide Croce Tags: Original Article Source Type: research

One Year Effectiveness Study of Intravitreous Ranibizumab in Neovascular Age ‐Related Macular Degeneration: A Meta‐Analysis
Abstract PurposeThe clinical efficacy of ranibizumab has been examined by a large number of prospective and retrospective studies to date. This meta‐analysis was conducted to summarize the current body of evidence on visual acuity (VA) changes with use of ranibizumab in the treatment of neovascular age‐related macular degeneration (wAMD). MethodsA literature review of multiple electronic databases (EMBASE, MEDLINE, MedMEME) was conducted to find randomized controlled trials (RCTs) and observational studies that reported changes in VA while patients with wAMD were on ranibizumab. Study factors analyzed were baseline pat...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 1, 2017 Category: Drugs & Pharmacology Authors: Michael Guo, Mahyar Etminan, Jasmine Cheng, Zafar Zafari, David Maberley Tags: Original Research Article Source Type: research

Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
Abstract PURPOSE: To evaluate choroidal thickness (CT) and retinal morphological changes in eyes with neovascular age-related macular degeneration (nAMD) following ranibizumab or aflibercept intravitreal treatment. MATERIALS AND METHODS: This was a prospective, observational, comparative study where 76 eyes of 76 consecutive patients with treatment-naive nAMD were consecutively enrolled and randomized to ranibizumab 0.5 mg or aflibercept 2 mg injections. Spectral-domain optical coherence tomography images of the choroid were obtained by enhanced depth imaging modality. CT measurements were made of t...
Source: Current Eye Research - November 22, 2017 Category: Opthalmology Authors: Gharbiya M, Giustolisi R, Marchiori J, Bruscolini A, Mallone F, Fameli V, Nebbioso M, Abdolrahimzadeh S Tags: Curr Eye Res Source Type: research

Efficacy of intravitreal aflibercept in macular telangiectasia type 1 is linked to the ocular angiogenic profile
Conclusion: The clinical response to aflibercept coupled to the angiogenic profile of MacTel 1 eyes support the implication of the placental growth factor/Flt-1 pathway in MacTel 1. (Source: RETINA)
Source: RETINA - November 21, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia
ConclusionsRanibizumab and aflibercept are dispensed in a similar manner by Australian pharmacies during the first year of treatment.FundingNovartis Pharma AG. (Source: Advances in Therapy)
Source: Advances in Therapy - November 21, 2017 Category: Drugs & Pharmacology Source Type: research

Relationship between visual outcomes and retinal fluid resorption in patients with diabetic macular edema treated with ranibizumab.
CONCLUSIONS: In this study, CRFR was required but not sufficient to achieve a VA>70 letters. PMID: 29132693 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - November 16, 2017 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Refractive changes after intravitreal ranibizumab injections for diabetic macular oedema
ConclusionsIntravitreal ranibizumab injections did not seem to affect the refractive power of patients with diabetic macular oedema. Therefore, appropriate spectacle correction can be prescribed any time during ongoing treatment with ranibizumab injections. (Source: Clinical and Experimental Optometry)
Source: Clinical and Experimental Optometry - November 14, 2017 Category: Opthalmology Authors: Irini Chatziralli, Athanasios Chatzipantelis, Eleni Dimitriou, Evgenia Mpourouki, George Theodossiadis, Panagiotis Theodossiadis Tags: Research Source Type: research

Refractive changes after intravitreal ranibizumab injections for diabetic macular oedema
Clinical and Experimental Optometry, EarlyView. (Source: Clinical and Experimental Optometry)
Source: Clinical and Experimental Optometry - November 14, 2017 Category: Opthalmology Source Type: research

Severe Gemella haemolysans endophthalmitis following ranibizumab intravitreal injection
We present a unique case of endophthalmitis with negative cultures and positive 16s ribosomal ribonucleic acid gene sequencing showing G. haemolysans infection after an intravitreal ranibizumab injection for wet age-related macular degeneration. (Source: Indian Journal of Ophthalmology)
Source: Indian Journal of Ophthalmology - November 13, 2017 Category: Opthalmology Authors: Silvia Olivia Salceanu Sarah Levy Richard Cunningham Kwabena Frimpong-Ansah Source Type: research

Renal damage associated to intravitreal administration of ranibizumab.
Authors: Morales E, Moliz C, Gutierrez E PMID: 29122213 [PubMed - in process] (Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia)
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - November 12, 2017 Category: Urology & Nephrology Tags: Nefrologia Source Type: research

Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
CONCLUSIONS: Subfoveal choroidal thickness decreased significantly after both of IVR and IVA injections in patients with nAMD. In conclusion, intravitreal injections of ranibizumab or aflibercept affect not only neovascular lesion but also the underlying choroid. PMID: 29113742 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - November 10, 2017 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with anti-VEGF therapy for diabetic macular edema: A Bayesian network meta-analysis
Conclusion There was no apparent difference on improving vision between SDMLP monotherapy and CLP monotherapy. The most effective treatment in the network was ranibizumab therapy combined with CLP followed by SDMLP monotherapy, Bevacizumab therapy combined with CLP, and CLP monotherapy in rank order. (Source: Biomedicine and Pharmacotherapy)
Source: Biomedicine and Pharmacotherapy - November 6, 2017 Category: Drugs & Pharmacology Source Type: research

Sequential tissue plasminogen activator, pneumatic displacement, and anti-VEGF treatment for submacular hemorrhage.
glu S Abstract PURPOSE: To report the results of our sequential intravitreal (IV) tissue plasminogen activator (tPA), pneumatic displacement (PD), and IV anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD)-related submacular hemorrhage (SMH). METHODS: A total of 16 eyes of 16 patients with SMH of less than 15 days duration were included in this retrospective pilot study. The tPA was applied on the day of diagnosis, and PD was performed the following day. Patients received 3 consecutive monthly IV injections of ranibizumab starting from ...
Source: European Journal of Ophthalmology - November 4, 2017 Category: Opthalmology Authors: Bardak H, Bardak Y, Erçalık Y, Erdem B, Arslan G, Timlioglu S Tags: Eur J Ophthalmol Source Type: research

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab.
Conclusions: Aflibercept intravitreal injection in patients with fibrovascular DEP due to nAMD who respond poorly to monthly ranibizumab led to short-term functional and anatomical improvement. Reduction of intravitreal injection frequency was obtained until 2 years of follow-up. PMID: 29093970 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - November 3, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
(Source: Clinical Interventions in Aging)
Source: Clinical Interventions in Aging - November 3, 2017 Category: Geriatrics Tags: Clinical Interventions in Aging Source Type: research

Subtenon Injections of Ranibizumab Arrest Growth in Early Recurrent Pterygium
Conclusions: In half of the subjects, subtenon ranibizumab appeared to arrest growth. Although the response is variable, this may warrant the drug's use when attempting to control growth of recurrent pterygia, and may prevent consecutive surgery for some patients. (Source: Eye and Contact Lens: Science and Clinical Practice)
Source: Eye and Contact Lens: Science and Clinical Practice - November 1, 2017 Category: Opthalmology Tags: Article Source Type: research

Concurrent injection of dexamethasone intravitreal implant and anti-angiogenic agent in patients with macular edema: A retrospective cohort study
Abstract To evaluate the safety and efficiency in macular edema patients who concurrently received a single injection of a dexamethasone intravitreal implant (DEX, 0.7 mg) and ranibizumab (2.3 mg). A retrospective cohort study was conducted, and medical records from 2012 to 2016 were reviewed. Patients who received concurrent DEX and ranibizumab injections with a follow-up period of at least 3 months were enrolled in the study group. An age and gender-matched group received ranibizumab injections and was designated the control group. The best-corrected visual acuity (BCVA), central macular thickness (CMT) and intrao...
Source: Medicine - November 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema
ConclusionThis study showed that ranibizumab plus laser is a valuable treatment option for the management of DME. Patients with DME in PDR might also benefit from combined therapy compared to laser alone. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - November 1, 2017 Category: Opthalmology Authors: Gabriele E. Lang, Sandra Liakopoulos, Jessica V ögeler, Claudia Weiß, Georg Spital, Maria‐Andreea Gamulescu, Chris Lohmann, Peter Wiedemann Tags: Original Article Source Type: research

Renal Function after Intravitreal Administration of Vascular Endothelial Growth Factor Inhibitors in Patients with Diabetes and Chronic Kidney Disease
This study aimed to determine whether intravitreal administration of vascular endothelial growth factor inhibitors is associated with deterioration of renal function, as seen with systemic administration, in patients with diabetes and chronic kidney disease. Estimated glomerular filtration rates before and after 160 intravitreal injections of vascular endothelial growth factor inhibitors (aflibercept, bevacizumab, or ranibizumab) were compared in 69 patients with diabetes and with a baseline estimated glomerular filtration rate
Source: Journal of Diabetes Investigation - November 1, 2017 Category: Endocrinology Authors: Yusuke Kameda, Tetsuya Babazono, Yasuko Uchigata, Shigehiko Kitano Tags: Short Report Source Type: research

Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
This randomized clinical trial compares the efficacy and safety of combination therapy of ranibizumab and verteporfin photodynamic therapy with ranibizumab monotherapy in polypoidal choroidal vasculopathy. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - November 1, 2017 Category: Opthalmology Source Type: research

The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema
Acta Ophthalmologica, EarlyView. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - November 1, 2017 Category: Opthalmology Source Type: research

Geographic and Demographic Variation in Use of Ranibizumab Versus Bevacizumab for Neovascular Age-related Macular Degeneration in the United States
To examine demographic and geographic variation in the use of ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) among Medicare beneficiaries. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - October 27, 2017 Category: Opthalmology Authors: Emily W. Gower, Joshua D. Stein, Nakul S. Shekhawat, Shravani Mikkilineni, Taylor S. Blachley, Nicholas M. Pajewski Tags: Original Articles Source Type: research

Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with anti-VEGF therapy for diabetic macular edema: A Bayesian network meta-analysis.
CONCLUSION: There was no apparent difference on improving vision between SDMLP monotherapy and CLP monotherapy. The most effective treatment in the network was ranibizumab therapy combined with CLP followed by SDMLP monotherapy, Bevacizumab therapy combined with CLP, and CLP monotherapy in rank order. PMID: 29091878 [PubMed - as supplied by publisher] (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 26, 2017 Category: Drugs & Pharmacology Authors: Wu Y, Ai P, Ai Z, Xu G Tags: Biomed Pharmacother Source Type: research

Laser-Induced Choroidal Neovascularizations: Clinical Study of 3 Cases
Conclusion: To prevent a laser-induced CNV, it is critical to avoid heavy small-spot laser burns and repeated application. Patients should be monitored carefully for CNV after laser treatment. In our cases, PDT and intravitreal ranibizumab injections were effective for the treatment of laser-induced CNV.Case Rep Ophthalmol 2017;8:429 –435 (Source: Case Reports in Ophthalmology)
Source: Case Reports in Ophthalmology - October 25, 2017 Category: Opthalmology Source Type: research